Truist raised the firm’s price target on SI-Bone (SIBN) to $22 from $20 and keeps a Buy rating on the shares after its Q1 results. The company drove a $2M revenue beat and delivered nice operating leverage as positive adjusted EBITDA was also above expectations, the analyst tells investors in a research note. SI-Bone is primed to beat and raise revenue through FY25, and the firm comes away from Q1 with additional confidence on the company’s EBITDA trajectory, Truist added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIBN:
- SI-Bone’s Strong Performance and Growth Potential Reinforce Buy Rating
- SI-Bone’s Strong Performance and Strategic Growth Initiatives Support Buy Rating
- SI-Bone’s Strong Q1 Performance and Strategic Initiatives Justify Buy Rating
- SI-Bone’s Strong Financial Performance and Growth Potential Justify Buy Rating
- SI-BONE, Inc. Reports Strong Q1 2025 Growth